New hints towards a precision medicine strategy for IDH wild-type glioblastoma

K. White, K. Connor, J. Clerkin, B. M. Murphy, M. Salvucci, A. C. O'Farrell, M. Rehm, D. O'Brien, J. H.M. Prehn, S. P. Niclou, M. L.M. Lamfers, M. Verreault, A. Idbaih, R. Verhaak, A. Golebiewska, A. T. Byrne*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Citations (Scopus)


Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.

Original languageEnglish
Pages (from-to)1679-1692
Number of pages14
JournalAnnals of Oncology
Issue number12
Publication statusPublished - Dec 2020


  • IDH-wt glioblastoma
  • multi-omics
  • precision therapy
  • tumour microenvironment


Dive into the research topics of 'New hints towards a precision medicine strategy for IDH wild-type glioblastoma'. Together they form a unique fingerprint.

Cite this